Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-002
- Development stage
- Phase 3
- Lead developer
- Jupiter Wellness
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
DA-002 is a topical pharmaceutical agent under investigation for the treatment of hair loss, specifically androgenetic alopecia and pattern baldness in both males and females. It acts as an alpha 1 agonist, with its ingredients having demonstrated hair growth effects in vitro. The drug is being evaluated for efficacy and safety compared to topical minoxidil. Mechanistically, it appears to target the integrin subunit alpha 1 (CD49a), functioning as an agonist at this site[1][2][3]. Clinical trials are ongoing to assess its potential benefit in promoting hair regrowth.
02
Targets
ITGA1 (Integrin Subunit Alpha 1)
Beyond the preview
Go deeper on DA-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-002.